Vivani Medical Inc.
IPO Year: 2014
Exchange: NASDAQ
Vivani Medical Inc. Press Releases
Fastest customizable press release news feed in the world
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into the second quarter of 2026, supporting further development of NPM-139 and NPM-115 programs in chronic weight management ALAMEDA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"),
Vivani Medical Announces $8.25M Private Placement Equity Financing
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement to issue and sell an aggregate of 7,366,071 shares, each at a price of $1.12 per share, expected to result in gross proceeds of approximately $8.25 million in a p
Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing smooth and steady delivery of GLP-1 therapy ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company de
Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to
Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now
MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investment community the opportunity to engage directly with Vivani President and CEO Adam Mendelsohn, Ph.D. Dr. Mendelsohn will provide an overview of the Company and, time permitting, open the floor to questions afterward. Please submit your questions
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic®/Wegovy® Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025 Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent's Orion® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second Sight Medical Products, Cortigent achieved the first and only FDA authorization (under a Humanitarian Device Exemption) for an artificial vision device called the Argus® II, which was marketed for a rare form of blindness and implanted in hundreds of patients Cortigent's precision neurostimulation technology is also being developed for the recovery of arm and hand motion in paralysis due to strok
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayJanuary 15, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back t
Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now
MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1January 15, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to the r
Vivani Medical Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,920 worth of shares (2,000 units at $0.96), increasing direct ownership by 5% to 38,500 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Williams Gregg bought $1,089 worth of shares (1,078 units at $1.01), increasing direct ownership by 0.15% to 727,608 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Williams Gregg bought $2,212 worth of shares (2,190 units at $1.01), increasing direct ownership by 0.30% to 726,530 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Williams Gregg bought $2,015 worth of shares (1,995 units at $1.01), increasing direct ownership by 0.28% to 724,340 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Williams Gregg bought $101 worth of shares (100 units at $1.01), increasing direct ownership by 0.01% to 722,345 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Vivani Medical Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Business Officer Dwyer Donald bought $4,100 worth of shares (4,000 units at $1.02), increasing direct ownership by 8% to 55,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,110 worth of shares (1,000 units at $1.11), increasing direct ownership by 2% to 51,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SEC Form 4 filed by Director Bradbury Daniel
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SEC Form 4 filed by Director Williams Gregg
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Director Williams Gregg bought $4,999,999 worth of shares (3,968,253 units at $1.26), increasing direct ownership by 545% to 4,695,861 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $2,835 worth of shares (2,500 units at $1.13), increasing direct ownership by 5% to 50,000 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $11,120 worth of shares (9,000 units at $1.24), increasing direct ownership by 23% to 47,500 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Chief Business Officer Dwyer Donald bought $1,920 worth of shares (2,000 units at $0.96), increasing direct ownership by 5% to 38,500 units (SEC Form 4)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SEC Form 4 filed by Director Williams Gregg
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SEC Form 4 filed by Director Baker Wilford Dean
4 - Vivani Medical, Inc. (0001266806) (Issuer)
Vivani Medical Inc. SEC Filings
SEC Form 10-K filed by Vivani Medical Inc.
10-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
SEC Form 10-Q filed by Vivani Medical Inc.
10-Q - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Vivani Medical Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SEC Form SC 13D filed by Vivani Medical Inc.
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)